https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261009 BiopharmaWatch en 2026-10-09T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/CCEL/cryo-cell-reports-fiscal-q3-2026-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVH/evolent-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grant-nyse-american BiopharmaWatch en 2026-10-09T20:15:29.000Z AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-1-15-billion-offerings BiopharmaWatch en 2026-10-09T20:05:09.000Z Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes https://www.biopharmawatch.com/news/ACH/accendra-health-nyse-listing-standard-notice BiopharmaWatch en 2026-10-09T20:05:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-09T20:05:00.000Z Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ASTH/astrana-health-q3-financial-results-2026 BiopharmaWatch en 2026-10-09T20:05:00.000Z Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/AGEN/agenus-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-09T19:23:00.000Z Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference https://www.biopharmawatch.com/news/VRTX/vertex-alytfrek-data-north-american-cystic-fibrosis-conference BiopharmaWatch en 2026-10-09T17:15:00.000Z Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/BIAF/wallachbeth-capital-announces-closing-bioaffinity-technologies-4-million-registered-direct BiopharmaWatch en 2026-10-09T16:30:00.000Z WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-thinkequity-conference-2026 BiopharmaWatch en 2026-10-09T16:05:00.000Z Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-inc-announces-closing-4-million-registered-direct-financing BiopharmaWatch en 2026-10-09T15:37:00.000Z bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BMRN/biomarin-advances-achondroplasia-hypochondroplasia-treatment BiopharmaWatch en 2026-10-09T13:05:00.000Z BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting https://www.biopharmawatch.com/news/HCWB/hcw-biologics-ind-application-solid-tumors BiopharmaWatch en 2026-10-09T13:00:00.000Z HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-aha-hypertension-sessions-2026 BiopharmaWatch en 2026-10-09T13:00:00.000Z Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 https://www.biopharmawatch.com/news/CLGN/collplant-announces-private-placement-3-7-million BiopharmaWatch en 2026-10-09T13:00:00.000Z COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT https://www.biopharmawatch.com/news/RPRX/royalty-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-09T12:53:25.000Z Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-greg-dipasquale-cco BiopharmaWatch en 2026-10-09T12:30:00.000Z Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-data-eadv-fall-clinical BiopharmaWatch en 2026-10-09T12:00:27.000Z Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q3-2026-earnings-release BiopharmaWatch en 2026-10-09T12:00:00.000Z Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/NTRA/fda-breakthrough-device-natera-multi-cancer-assay BiopharmaWatch en 2026-10-09T12:00:00.000Z FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-agreement-shareholder-participation BiopharmaWatch en 2026-10-09T12:00:00.000Z Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-revera-301-european-participant BiopharmaWatch en 2026-10-09T12:00:00.000Z Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-acg-ueg-conferences-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-relaunches-irulya-therapeutics BiopharmaWatch en 2026-10-09T12:00:00.000Z Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Filana Therapeutics to Participate in the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/TLX/profound-telix-co-education-agreement-psma-prostate-care BiopharmaWatch en 2026-10-09T11:45:00.000Z Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-closes-public-offering-20-million BiopharmaWatch en 2026-10-09T11:17:00.000Z Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-present-canaccord-genuity-drug-device-conference BiopharmaWatch en 2026-10-09T11:05:00.000Z Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-virtual-investor-day-october-2026 BiopharmaWatch en 2026-10-09T11:00:13.000Z X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders https://www.biopharmawatch.com/news/JNJ/johnson-johnson-icotyde-long-term-results-plaque-psoriasis BiopharmaWatch en 2026-10-09T11:00:00.000Z New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis https://www.biopharmawatch.com/news/TEVA/teva-fda-approval-weltruza-olanzapine-injection BiopharmaWatch en 2026-10-09T11:00:00.000Z Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-glyphago-phase-1-data-ecnp-2026 BiopharmaWatch en 2026-10-09T11:00:00.000Z Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress https://www.biopharmawatch.com/news/GKOS/glaukos-phase-4-trial-idose-tr-cataract-surgery BiopharmaWatch en 2026-10-09T11:00:00.000Z Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261009 BiopharmaWatch en 2026-10-09T11:00:00.000Z Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SGMT/sagimet-denifanstat-phase-3-results-dermatology-conference BiopharmaWatch en 2026-10-09T11:00:00.000Z Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference https://www.biopharmawatch.com/news/LLY/new-phase-3b-data-lilly-taltz-zepbound-psoriasis-obesity BiopharmaWatch en 2026-10-09T10:45:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-inducement-grants-new-employees BiopharmaWatch en 2026-10-09T08:42:00.000Z LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VOGX/vogenx-appoints-richard-gorman-cfo BiopharmaWatch en 2026-10-09T08:00:00.000Z Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer https://www.biopharmawatch.com/news/ALMS/alumis-phase-3-envudeucitinib-psoriasis-data BiopharmaWatch en 2026-10-09T08:00:00.000Z Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-needle-free-radiation-preparedness BiopharmaWatch en 2026-10-09T07:45:00.000Z Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers https://www.biopharmawatch.com/news/PHVS/deucrictibant-phase-3-study-results-hai-attack BiopharmaWatch en 2026-10-08T22:35:00.000Z Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet https://www.biopharmawatch.com/news/CVS/aetna-2027-star-ratings-clinical-quality-member-experience BiopharmaWatch en 2026-10-08T22:03:00.000Z Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-cms-2027-star-ratings BiopharmaWatch en 2026-10-08T21:00:00.000Z Alignment Healthcare Earns 4 Stars or Higher for Six of Seven Eligible Medicare Advantage Contracts in CMS 2027 Star Ratings https://www.biopharmawatch.com/news/AGEN/armenian-authorization-agenus-bot-bal-mcrc BiopharmaWatch en 2026-10-08T20:41:00.000Z Riassunto: L’Armenia concede le prime autorizzazioni alla commercializzazione di Agenus BOT+BAL per la terapia del carcinoma colorettale metastatico MSS già trattato https://www.biopharmawatch.com/news/AGEN/armenian-approval-for-agenus-bot-bal-mcrc BiopharmaWatch en 2026-10-08T20:41:00.000Z Samenvatting: Armenië verleent eerste vergunningen om Agenus’ BOT+BAL ten behoeve van eerder behandeld MSS gemetastaseerd colorectaal carcinoom in de handel te brengen https://www.biopharmawatch.com/news/AGEN/armenien-marktzulassungen-bot-bal-agenus BiopharmaWatch en 2026-10-08T20:40:00.000Z Armenien erteilt erste Marktzulassungen für BOT+BAL von Agenus bei zuvor behandeltem MSS-metastasiertem Kolorektalkarzinom https://www.biopharmawatch.com/news/SION/sionna-therapeutics-nacfc-2026-data-presentation BiopharmaWatch en 2026-10-08T20:30:07.000Z Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/CON/concentra-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-08T20:30:00.000Z Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/ZTS/zoetis-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-08T20:15:00.000Z Zoetis Declares Fourth Quarter 2026 Dividend https://www.biopharmawatch.com/news/BDX/bd-announces-financial-results-q4-fiscal-2026 BiopharmaWatch en 2026-10-08T20:15:00.000Z BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026 https://www.biopharmawatch.com/news/BKD/brookdale-reports-september-2026-occupancy BiopharmaWatch en 2026-10-08T20:15:00.000Z Brookdale Reports September 2026 Occupancy https://www.biopharmawatch.com/news/GH/guardant-health-guardant360-cdx-approval-europe BiopharmaWatch en 2026-10-08T20:12:00.000Z Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-autonomous-lab-nsf-x-labs BiopharmaWatch en 2026-10-08T20:10:00.000Z Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program https://www.biopharmawatch.com/news/ILMN/illumina-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-08T20:06:00.000Z Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/AGMB/agomab-ontunisertib-ueg-week-2026 BiopharmaWatch en 2026-10-08T20:05:08.000Z Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-transactions-persons-discharging-managerial-20261008 BiopharmaWatch en 2026-10-08T20:05:07.000Z Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-10-08T20:05:00.000Z Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-givastomig-esmo-2026 BiopharmaWatch en 2026-10-08T20:05:00.000Z NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026 https://www.biopharmawatch.com/news/ABCL/abcellera-phase-1-2-data-abcl635-tms-2026 BiopharmaWatch en 2026-10-08T20:05:00.000Z AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-mps-iiib-data-presentation BiopharmaWatch en 2026-10-08T20:05:00.000Z Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting https://www.biopharmawatch.com/news/GH/guardant-health-third-quarter-2026-results BiopharmaWatch en 2026-10-08T20:05:00.000Z Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LKFT/lakefront-transparantieverklaring-bank-of-america BiopharmaWatch en 2026-10-08T20:01:00.000Z Lakefront ontvangt transparantieverklaring van Bank of America https://www.biopharmawatch.com/news/LKFT/lakefront-receives-transparency-notification-bank-america BiopharmaWatch en 2026-10-08T20:01:00.000Z Lakefront Receives Transparency Notification from Bank of America https://www.biopharmawatch.com/news/HIT/health-in-tech-launches-hitrx-broker-first-environment BiopharmaWatch en 2026-10-08T20:00:00.000Z Health In Tech Launches HitRix, a Broker-First Environment for Self-Funded Stop-Loss Placement https://www.biopharmawatch.com/news/STAA/staaar-surgical-names-andrew-pilon-vp-business-development BiopharmaWatch en 2026-10-08T19:14:00.000Z STAAR Surgical Names Andrew Pilon as Vice President of Business Development https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-4-million-financing BiopharmaWatch en 2026-10-08T17:30:00.000Z WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-financing-common-stock BiopharmaWatch en 2026-10-08T16:07:00.000Z bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules